Ayurveda has been found effective in treating Type 2 diabetes by maintaining blood sugar levels.

Ayurvedic herbs like turmeric may help control blood sugar levels and limit drug side effects in diabetes management.

The Indian government has established a ministry for alternative medicine and received $250 million from the WHO for research on traditional medicine.

Ashwagandha, an Indian herbal medicine, reduces anxiety, stress, and fatigue, and may treat long COVID symptoms.

The WHO has established a center in India to research traditional medicine and integrate it into health systems.

The interaction between Indian herbal medicines, such as Ashwagandha, and conventional treatments like antibiotics and depression inhibitors is a concern.

The CDSCO ensures the quality and safety of Indian medicines through regular testing and inspection.

Institutions like the National Institute of Pharmaceutical Education and Research promote Indian herbal medicine through research and education.

The Union AYUSH Ministry plans to set up a Global Centre for Traditional Medicine in Hyderabad.

The herbal medicine market was worth USD 201.06 billion in 2022 and is expected to reach USD 371.45 billion by 2030, growing at a 8.02% CAGR.

Indian herbal medicines, including Ayurveda, can help control blood sugar levels in Type 2 diabetes patients.

BGR-34, a herbal formulation, manages diabetes and contains compounds from daruharidra, gudmar, methi, and vijayasar.

A clinical trial on Ashwagandha for Long Covid is being conducted by the London School of Hygiene & Tropical Medicine and the All India Institute of Ayurveda.

The Indian government regulates phytopharmaceuticals, including Indian herbal medicines, and manufacturers must follow quality, safety, and efficacy standards.

Schedule M is to be revised to meet WHO standards, making Good Manufacturing Practices (GMP) mandatory for pharma companies, including those producing Indian herbal medicines.

Ayurveda has been found effective in treating Type 2 diabetes by maintaining blood sugar levels.

Title:

Content: News

Take up pilot project on Ayurveda treatment: MLA Ramdas

August 29, 2022

Mysore/Mysuru: Studies conducted across the world have found that several traditional medicines commonly used in India as part of Ayurveda are effective in maintaining blood sugar levels in patients with Type 2 diabetes.

Ayurveda is a traditional medical system that has been used for thousands of years in India and some of the herbs included are also used in other parts of the world. In this direction, a systematic project must be developed to treat diabetes, suggested MLA S.A. Ramdas. The suggestion was accepted by Ayurveda practitioners and experts in the field.

The MLA was speaking after inaugurating a free Ayurvedic treatment camp organised at the Sri Ganapathy Ashram on Nanjangud Road yesterday. The camp was organised inside the auditorium of Lakshminarasimha Kuteera of the Ashram by the Government Ayurvedic Research Centre and Ayurveda Academy of Chamarajpet in Bengaluru.

Ramdas suggested the doctors and officers launch a pilot project in a particular locality or a Ward and assured of making all facilities on behalf of the Government. He said that the project can be taken up on Sept. 17, the birthday of Prime Minister Narendra Modi for one year to achieve tangible results for the target population, he suggested.

Modern diabetes drugs are known for side effects and toxicity while Ayurveda works by controlling blood sugar and limiting the harmful effects of other drugs. Turmeric, for example, has been used for the treatment of diabetes in Ayurveda and traditional Chinese medicine, he added.

He said new Ayurvedic remedies were still in great demand for treating diabetes because of the limited efficacy and undesirable side effects of current drugs. A multi-pronged and individualised approach must be used to manage health conditions such as lifestyle modification, Ayurvedic detoxifying and purifying therapies and Ayurvedic medicines containing plant, animal, or mineral-origin ingredients, he added.

University of Mysore Vice-Chancellor Prof. G. Hemantha Kumar, Assistant Director of Government Ayurvedic Research Centre Dr. Lakshminarayana Shenoy, Joint Secretary of Ayurveda Academy Dr. Prashanth Ghokale, Junior pontiff of Ganapathy Ashram Datta Vijayananda Theertha Swamiji and others were present.

ABOUT

Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 41 years, Star of Mysore has been the newspaper that Mysureans reach for every evening to know about the happenings in Mysuru city. The newspaper has feature rich articles and dedicated pages targeted at readers across the demographic spectrum of Mysuru city. With a readership of over 2,50,000 Star of Mysore has been the best connection between it’s readers and their leaders; between advertisers and customers; between Mysuru and Mysureans.

CONTACT

Academy News Papers Private Limited, Publishers, Star of Mysore & Mysuru Mithra, 15-C, Industrial ‘A’ Layout, Bannimantap, Mysuru-570015. Phone no. – 0821 249 6520

To advertise on Star of Mysore, email us at

Print Editon: [email protected]
For News/Press Release: [email protected]

In what areas have the medical uses of traditional Indian medicine been studied?

What does traditional Indian medicine generally treat?

It addresses the physical aspects of health conditions.

Ayurvedic herbs like turmeric may help control blood sugar levels and limit drug side effects in diabetes management.

In what areas have the medical uses of traditional Indian medicine been studied?

What does traditional Indian medicine generally treat?

It addresses the physical aspects of health conditions.

The Indian government has established a ministry for alternative medicine and received $250 million from the WHO for research on traditional medicine.

Title:

Content: Archive / Lifestyle
The World Health Organization is interested in alternative medicine.
Mohamed Ismail - Cairo - DPA -
Many people use traditional medicine – but what do these methods really do?
A new WHO centre intends to explore this.
The center is based in India, a country where alternative medicine is so important that it even has its own ministry – which specializes in Ayurveda, Yoga, Physiotherapy, Greek Medicine, Master and Homeopathy.
Indian Prime Minister Narendra Modi attended the opening of the centre in Jamnagar in mid-April, saying: “India ’ s traditional medicine system is not just a cure.
It ’ s a comprehensive science of life. ”
According to the World Health Organization (WHO), the Indian government is supporting the centre with US $250 million (230 million euros).
WHO President Tedros Adhanom Ghebreyesus said: “The center aims to be an engine of innovation, moving towards an agenda of evidence, data and sustainability in traditional medicine, ” adding that the center would connect traditional medicine practitioners around the world and help set standards for research.
Traditional medicine is a broad field.
According to the World Health Organization ’ s statement for the center, 80% of the world ’ s population uses traditional medicine, which includes among other things acupuncture, Ayurvedic medicine and herbal blends.
Traditional medicine is also represented in modern science.
According to the World Health Organization, about 40% of all drugs approved today are derived from natural substances.
The discovery of aspirin, for example, is based on ancient recipes made from the bark of the willow tree.
The research for artemisinin for use in the fight against malaria, for which the Nobel Prize was awarded in 2015, began with the study of ancient texts of Chinese medicine.
George Rochmeyer of Cochrane, an international network that provides the scientific basis for decisions in the health field, said it makes sense at least to take a closer look at treatment methods that have been developed over centuries, to verify the reasonableness of these methods, and to conduct clinical studies on them in case of doubt.
Cochrane reviews are systematic reviews that collect all scientific evidence on a specific issue from medicine or other health sciences.
However, Rochmeyer also stressed that besides the examples of traditional methods cited by the WHO, which form the basis of currently developed treatments, there are likely many other examples where traditional methods of careful review have proven ineffective or even dangerous, such as phlebotomy, noting that spending too much money on studies to review a therapeutic practice is always a matter of discretion.
Rochmeyer stated that there are many Cochrane reviews about the use of traditional methods such as acupuncture in certain cases, but: “From my personal experience at Cochrane, I would say that I have not come across many reviews that have shown really compelling evidence for traditional therapeutic practice. ”
This is often due to the fact that when searching for these treatments we find only a few often-poorly conducted studies that cannot prove or disprove any benefit from them – which brings us back to the question of whether the already limited research funds should be invested in a scientifically unreasonable procedure – for example, homeopathy.
Professor Emeritus Edzard Ernst, a longtime professor of alternative medicine at the University of Exeter, noted that while it was necessary to wait and see who would lead the center and what it would do, the WHO press release was full of exaggerations.
The World Health Organization says it also wants to use new technologies at the new center for the study of traditional medicine — via artificial intelligence and big data, for example.
The center is expected to focus on providing a reliable evidence base for policy and standards of traditional medicine practices and products.
In addition, the center is supposed to help countries integrate these practices into their health systems.
You may also read.

Ashwagandha, an Indian herbal medicine, reduces anxiety, stress, and fatigue, and may treat long COVID symptoms.

Title:

Content: Tuesday 10 August 2021 1:10 pm

Long Covid cure? Researchers to trial traditional Indian herb treatment

The London School of Hygiene & Tropical Medicine will work with the All India Institute of Ayurveda to determine whether a traditional Indian herb can help people recover from long Covid.

Ashwagandha, commonly known as Indian winter cherry, is traditionally used in the Indian Ayurvedic system of medicine to boost energy, reduce stress and strengthen the immune system.

Experts said recent trials had proven the herb’s efficacy in reducing anxiety, stress, improving muscle strength and reducing fatigue symptoms in patients with chronic diseases.

Long Covid patients can suffer from cognitive dysfunction, poor mental health, extreme fatigue and muscle weakness.

It is estimated these symptoms affect 10 to 20 per cent of Covid survivors and can last for one to three months or longer in many cases.

The study, funded by the Ministry of Ayush of the Government of India, will include a double-blind clinical trial involving 2,000 people living in the UK with long Covid.

Half of the trial participants will take 500mg Ashwagandha tablets twice a day for three months, while the other half will be given a placebo.

Researchers will randomly select participants to have a monthly follow-up of self-reported quality of life, impairment to activities of daily living, mental and physical health symptoms, supplement use and adverse events.

The study is expected to last for over a year.

“Ashwagandha has been shown to reduce symptoms of other conditions that are similar to those of long Covid, so we are hopeful that it will be an effective way to combat the condition,” said Sanjay Kinra, professor in clinical epidemiology at the London School of Hygiene & Tropical Medicine.

The research is also supported by the UK’s All-Party Parliamentary Group on Indian Traditional Sciences and the Traditional Complementary and Integrative Medicine Unit at the World Health Organisation (WHO).

Research is the only way to ensure appropriate integration of traditional medicine knowledge into mainstream medical practice,” said technical officer at WHO Geneva, Geetha Krishnan, who helped to facilitate the research project.

Share

In what areas have the medical uses of traditional Indian medicine been studied?

What does traditional Indian medicine generally treat?

It addresses the psychological aspects of health conditions.

What mental health problems does traditional Indian medicine treat?

Support the management of symptoms related to mental health.

The WHO has established a center in India to research traditional medicine and integrate it into health systems.

The interaction between Indian herbal medicines, such as Ashwagandha, and conventional treatments like antibiotics and depression inhibitors is a concern.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
The controversial Ashwagandha herb on social media..
Everything you need to know about her
Ashwagandha is a medicinal herb used in traditional Indian medicine (Ayurveda) for centuries and has become controversial on social media due to some interesting claims about its potential benefits.
However, we should treat this information with caution and regard it as public information.
Dr. Abdulrahman Shams, a nutritionist, revealed in special statements to Sada Al-Balad, the following are some of the main points of your knowledge of this herb and the possible allegations about it:
1.
Traditional use: Ashwagandha is believed to have soothing, anti-inflammatory and anti-stress properties.
It has been used in the Indian tradition to treat a variety of conditions such as stress, anxiety, sleep disorders and fatigue.
1.
Scientific research: There are some scientific studies that support some of the potential benefits of ashwagandha.
Some research has shown its potential effect in reducing anxiety levels, improving sleep, and supporting mental functioning.
However, more research is still needed to confirm the efficacy and safety of this herb.
1.
Side Possibilities: Typically, ashwagandha is considered safe when taken in moderate doses.
However, some minor side effects such as drowsiness or digestive disorders may occur.
Consult your doctor before taking ashwagandha, especially if you have an existing medical condition or are taking other medications.
1.
Drug interactions: Interactions may occur between ashwagandha and some other drugs.
It is advised not to take ashwagandha if you are taking medications such as antibiotics, depression inhibitors or thyroid medications, unless you consult your doctor.
You should remember that ashwagandha is not an officially recognized remedy for any health condition.
If you are considering using them, you should consult your physician or use a specialist healthcare practitioner for personal advice and guidance appropriate to your individual health condition.

The CDSCO ensures the quality and safety of Indian medicines through regular testing and inspection.

Title:

Content: Made-in-Himachal Pradesh drug samples fail quality test; max from Baddi

22 drugs manufacturers in Himachal Pradesh failed the quality test by CDSCO for sub-standard drugs like Zee Laboratories and Daxin Pharmaceuticals.
SHIMLA: As many as 22 drugs manufacturers in Himachal Pradesh have failed the quality test run by the Central Drugs Standard Control Organisation (CDSCO). In an alert issued for the month of May, the CDSCO has declared the drug samples to be of sub-standard quality. Of the total failed drug samples, 16 have been manufactured at Baddi in Solan, 5 in Paonta Sahib and Kala Amb in Sirmaur and 1 in Una.The drugs are used for treating ailments including throat infection, high blood pressure, cancer, infections, ulcer, cough, acidity and fever etc.
As per the CDSCO alert, three samples of Zee Laboratories, a pharma unit based in Paonta Sahib, and two samples of Baddi-based Daxin Pharmaceuticals, have failed quality test. A total 52 samples from all over the country have been declared to be of sub-standard quality by the CDSCO, a central drug regulatory body that approves and bans drugs and also conducts monthly clinical trials to test the quality of drugs. As per the state’s Drug Control Administration (DCA), the drugs whose samples failed would be withdrawn from the markets and manufacturers would be issued notices. Since January this year, 55 drug samples have failed the CDSCO drug quality test. Last month in April, 6 drugs manufactured in Himachal Pradesh failed the CDSCO quality test, 20 drugs in March, 21 in February and 14 in January.
In 2023, as many as 120 drugs, manufactured in Himachal Pradesh, had failed the CDSCO test. There are a total 660 pharmaceutical companies based in Himachal Pradesh with majority of them in Baddi, which is one of the biggest pharma hubs of the country. Along with CDSCO, drug samples are sent for testing to the Composite Testing Laboratory, Kandaghat in Solan and Regional Drug Testing Laboratory, Chandigarh. tnn
We also published the following articles recently

AstraZeneca's breast cancer drug fails in late-stage trial test
AstraZeneca's breast cancer drug Truqap failed to meet main goals in late-stage trial for metastatic triple-negative breast cancer patients.
Properties of drug peddlers to be frozen within week: CM
Punjab CM Bhagwant Mann unveils strategy to dismantle drug trade nexus with police reforms. Officers involved to face dismissal and property freezing. Thousands of police transfers made to break nexus.
Nagpur hit-&-run: Cop benched for 48-hr delay in sending blood samples for test
Nagpur police commissioner suspends senior inspector for delay in sending blood samples of hit-and-run case accused for alcohol testing after car accident kills two and injures 15 near Dighori toll naka.
End of Article
FOLLOW US ON SOCIAL MEDIA

Institutions like the National Institute of Pharmaceutical Education and Research promote Indian herbal medicine through research and education.

Title:

Content: Telangana

Centre in favour of locating global centre for traditional medicine in Hyderabad

The city is likely to have another jewel in its crown if the Central Government’s latest request relating to the setting up of a global centre for traditional medicine proposed by the World Health Organisation (WHO) is any indication.

Union Minister for Tourism, Culture and Development of North East Region G. Kishan Reddy has requested the State Government to identify a suitable parcel of land for setting up the institute in the city. In a letter addressed to Chief Minister K. Chandrasekhar Rao, the Union Minister asked him to resolve the issues pertaining to identification of land and spot a parcel of land.

He said that the country is known for its traditional medicines, including Ayurveda, yoga, Unani, naturopathy, Sowa-Ripa and Siddha to name a few, which are recognised worldwide. The COVID pandemic had further highlighted the benefits of traditional medicine and demonstrated the power of Ayurveda to the world.

“India is regarded as the pharmacy of the world and focus on traditional medicine aligns with Prime Minister Narendra Modi’s emphasis on prevention of diseases and wellness,” he said. He recalled that the WHO director general had announced intentions of setting up a global centre for traditional medicine in India on the occasion of World Ayurveda Day in November 2020.

The Union AYUSH Ministry was considering setting up of the centre in Hyderabad as traditional scientific research institutions like CCMB, CSIR, NIN, IICT, and FDTRC would further complement the approach towards an integrated holistic medicine. The Government of Telangana had been communicated for their inputs on the extent of support for setting up of the global centre, he said, adding that the global centre would benefit the city and the State.

Our code of editorial values

Printable version | Feb 18, 2022 8:35:17 pm | https://www.thehindu.com/news/national/telangana/centre-in-favour-of-locating-global-centre-for-traditional-medicine-in-hyderabad/article65062674.ece

The Union AYUSH Ministry plans to set up a Global Centre for Traditional Medicine in Hyderabad.

The herbal medicine market was worth USD 201.06 billion in 2022 and is expected to reach USD 371.45 billion by 2030, growing at a 8.02% CAGR.

Title:

Content: Herbal Medicine Market Size to Reach USD 371.45 Billion by 2030 | Exclusive Report by Fortune Business Insights™

Key Companies in Herbal Medicine Market are Cultivator Natural Products Pvt. Ltd. (India), 21ST Century HealthCare, Inc. (U.S.), Herbalife Nutrition (U.S.), ZeinPharma Germany GmbH (Germany), Blackmores Limited (Australia), Himalaya Global Holdings Ltd. (India), Nutraceutical Corporation (U.S.), Emami Limited (India), Nature's Answer, LLC. (U.S.), Patanjali Ayurved Limited (India), and more players profiled.

Pune INDIA

Pune, India, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global herbal medicine market size was valued at USD 201.06 billion in 2022 and is expected to be worth USD 216.40 billion in 2023. The market is projected to reach USD 371.45 billion by 2030, recording a CAGR of 8.02% during the forecast period.

Herbal medicines are made from natural ingredients to treat a wide range of diseases and improve an individual’s immunity level. Since there has been a drastic change in people’s lifestyle, the incidence of cardiovascular diseases and chronic stress are on the rise. These factors are expected to boost the adoption of herbal medicines as they claim to have no side-effects, unlike the conventional ones.

Get a Free Sample PDF Brochure:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/herbal-medicine-market-106320

Leading Players Featured in the Research Report:

Companies leading Herbal Medicine Market are Cultivator Natural Products Pvt. Ltd. (India), 21ST Century HealthCare, Inc. (U.S.), Herbalife Nutrition (U.S.), ZeinPharma Germany GmbH (Germany), Blackmores Limited (Australia), Himalaya Global Holdings Ltd. (India), Nutraceutical Corporation (U.S.), Emami Limited (India), Nature's Answer, LLC. (U.S.), Patanjali Ayurved Limited (India)

Report Scope & Segmentation:

Report Attributes Details
Forecast Period 2023-2030
Forecast CAGR 8.02%
2030 Value Projection USD 371.45 Billion
Herbal Medicine Market Size in 2022 USD 201.06 Billion
Historical Data 2019-2021
No. of Pages 208
Report Coverage Revenue Forecast, Company Profiles, Competitive Landscape, Growth Factors and Latest Trends
Segments Covered
  • By Application
  • By Form
  • By Region
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Herbal Medicine Market Growth Drivers Growing Adoption of Herbal Ingredients in Cosmetic Products to Boost Market Growth

Browse Summary of this Research Report:

https://www.fortunebusinessinsights.com/herbal-medicine-market-106320

COVID-19 Impact:

Growing Health Concerns During Pandemic Boosted Product Demand

The healthcare and pharma industries experienced long and short-term effects of the pandemic as there were several delays in R&D and manufacturing activities to produce effective medicines for the infection. This situation made people more concerned about their health and wellbeing, which boosted the consumption of dietary supplements and immunity boosters that were made from natural ingredients. This accelerated the market’s progress.

Segmentation:

Growing Usage of Herbal Ingredients in Nutraceuticals and Pharma Products to Boost Market Progress

In terms of application, the market is divided into pharmaceutical & nutraceutical, food & beverages, and personal care & beauty products. The pharmaceutical & nutraceutical segment holds the largest herbal medicine market share as herbal ingredients are increasingly used in dietary supplements and medicines to enhance their performance.

Rising Availability of Herbal Medicines in Tablet & Capsule Form to Augment Market Development

Based on form, the market is segmented into powder, liquid & gel, and tablets & capsules. The tablets & capsules segment is expected to capture the leading market share as herbal medicines are produced in the form of tablets and capsules to ease their access to patients.

With respect to region, the market covers North America, Europe, Asia Pacific, South America, and the Middle East & Africa.

Report Coverage:

The research report offers an in-depth analysis of the market and highlights key aspects, such as leading types, companies, and top product forms. It also provides valuable insights into the market segments and trends, while covering key industry developments. Besides the aforementioned factors, the report encompasses many factors that have contributed to the market's growth in recent years.

Ask for Customization:

https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/herbal-medicine-market-106320

Drivers and Restraints:

Growing Adoption of Herbal Ingredients in Cosmetic Products to Boost Market Growth

Exporters of herbal ingredients in the developing countries are viewing the cosmetics industry as a viable medium to help them expand their operations overseas. A growing number of cosmetics manufacturing companies are incorporating natural ingredients to cater to the robust demand for cosmetics that are good for the face, skin, and body. They are replacing synthetic chemicals with herbal ingredients to boost their product’s performance and expand their customer base.

However, stringent guidelines with respect to using herbal ingredients as raw materials may hinder the herbal medicine market growth.

Regional Insights:

Europe Market to Expand Due to Growing Product Usage in Cosmetics Sector

Europe is expected to lead the global herbal medicine market as the region has a vast cosmetics sector. This can present lucrative opportunities for emerging companies that develop and supply herbal ingredient-based products. Many cosmetic companies across the region are witnessing a strong rise in the demand for personal care & beauty products that are made from natural ingredients. This factor will spur the regional market growth.

North America will also grow at a significant pace as customers across the region are becoming more conscious about their health and wellbeing, which has increased the consumption of dietary supplements.

Competitive Landscape:

Key Companies to Use Various Strategies to Boost Their Product Sales

Some of the major companies in the market include ZeinPharma Germany GmbH, Cultivator Natural Products Pvt. Ltd., Blackmores Limited, Herbalife Nutrition, and many others. They are implementing various strategies, such as partnerships and new product launches to increase their product sales and expand their presence in the global market.

Speak to Analyst:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/herbal-medicine-market-106320

Major Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
    • Market Trends
  • Key Insights
    • Overview on the Parent Market
    • Supply Chain Analysis
    • Industry SWOT Analysis
    • Recent Industry Developments - Policies, Mergers & Acquisitions, and New Product Launches
    • Market Analysis and Insights (in Relation with COVID-19)
      • Impact of COVID-19 on the Market
      • Supply Chain Challenges due to the Pandemic
      • Potential Opportunities Due to COVID-19
  • Global Herbal Medicine Market Analysis, Insights and Forecast, 2019-2030
    • Key Findings / Summary
    • Market Size Estimates and Forecast
      • By Form (Value)
        • Powder
        • Liquid & Gel
        • Tablets & Capsules
      • By Application (Value)
        • Pharmaceutical & Nutraceutical
        • Food & Beverages
        • Personal Care & Beauty Products
      • By Region (Value)
        • North America
        • Europe
        • Asia Pacific
        • South America
        • Middle East & Africa
  • North America Herbal Medicine Market Analysis, Insights and Forecast, 2019-2030
    • Key Findings / Summary
    • Market Size Estimates and Forecast
      • By Form (Value)
        • Powder
        • Liquid & Gel
        • Tablets & Capsules
        • Others
      • By Application (Value)
        • Pharmaceutical & Nutraceutical
        • Food & Beverages
        • Personal Care & Beauty Products
      • By Country (Value)
        • U.S.
          • By Application (Value)
            • Pharmaceutical & Nutraceutical
            • Food & Beverages
            • Personal Care & Beauty Products
        • Canada
          • By Application (Value)
            • Pharmaceutical & Nutraceutical
            • Food & Beverages
            • Personal Care & Beauty Products
        • Mexico
          • By Application (Value)
            • Pharmaceutical & Nutraceutical
            • Food & Beverages
            • Personal Care & Beauty Products

To Be Continued…!

Inquire Before Buying:

https://www.fortunebusinessinsights.com/enquiry/queries/herbal-medicine-market-106320

Key Industry Development:

December 2022 – Dabur expanded its Ayurvedic medicines portfolio by introducing Ratnaprash Sugar-Free and Aampachak Kkadha. The former is said to be good for health and provides strength and stamina, whereas the latter strengthens the digestive system and contains herbs, such as shunthi, bhumiamla, harad, pippali, and others.

Read Related Insights:

By 2028, Dietary Supplements Market to Achieve USD 128.64 Billion | Exclusive Research Report by Fortune Business Insights™

Nutraceuticals Market to Hit USD 658.11 Billion by 2028 | With 9.3% of CAGR

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

9th Floor, Icon Tower,

Baner - Mahalunge Road,

Baner, Pune-411045, Maharashtra, India.

Phone:

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email:sales@fortunebusinessinsights.com

Fortune Business Insights™

Linkedin |Twitter |Blogs

Attachment

Indian herbal medicines, including Ayurveda, can help control blood sugar levels in Type 2 diabetes patients.

In what areas have the medical uses of traditional Indian medicine been studied?

What does Berberine, a commonly used herbal material in traditional Indian medicine, treat?

What does traditional Indian medicine generally treat?

It addresses the physical aspects of health conditions.

What have recent studies revealed about curry leave, a herb used in traditional Indian medicine?

It helps control the severity of diabetes.

BGR-34, a herbal formulation, manages diabetes and contains compounds from daruharidra, gudmar, methi, and vijayasar.

Title:

Content: Nation

Researchers claim 400 medicinal plants have anti-diabetic properties

X

New Delhi: As a part of its initiatives to reduce the diabetic burden, the scientists have emphasised on exploring the anti-diabetic properties of around 400 medicinal plants to be used in making medicines based on ayurvedic formulations to control type-2 diabetes by reducing sugar level in blood.

According to the researchers from Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry and All India Institute of Medical Sciences, Kalyani, as of now, there are 21 herbal plants, including Vijayasar, Jamun, Cumin, Daruharidra, little gourd, bael, fenugreek, neem, amla, turmeric that have been found to have prominent anti-hyperglycemic action.

Stressing that diabetes cure lies in the nature, the researchers asserted that intensive studies have been done on 21 herbs and in-depth research on at least 400 herbal plants is needed to exhibit their anti-diabetic properties..

As per their research paper, which is published in the World Journal of Diabetes, these medicinal plants have been the basis of many drugs to manage diabetes. The researchers have also cited the example of BGR-34, a herbal formulation developed by the

Council of Scientific and Industrial Research (CSIR), which has been used to manage diabetes.

The herbal drug BGR-34 contains not one, but many active compounds derived from four medicinal herbs daruharidra, gudmar, methi and vijayasar. Apart from this, giloe and majeeth have also been added to increase immunity as well as antioxidants levels, said Dr Sanchit Sharma, executive director, AIMIL Pharmaceuticals.

The study titled “Treatment on Nature’s lap: Use of Herbal Products in the Management of Hyperglycemia” stated

that although partial research conducted on eight plants, including pomegranate, shilajit, bean, tea, ginkgo biloba, and saffron demonstrate anti-diabetic properties,

it emphasised the need for further trials.

A recent study conducted by AIIMS Delhi revealed that BGR-34, an Ayurvedic medicine, not only helps in reducing sugar levels but also addresses obesity.

The researchers also noted that several allopathic drugs used in diabetes management have their origins in herbal remedies.

For instance, metformin, a widely prescribed medication, is derived from the Galega officinalis plant, which

was historically used to treat diabetes in 19th century Europe.

Next Story

In what areas have the medical uses of traditional Indian medicine been studied?

A clinical trial on Ashwagandha for Long Covid is being conducted by the London School of Hygiene & Tropical Medicine and the All India Institute of Ayurveda.

What is the traditional Indian medical system called?

The Indian government regulates phytopharmaceuticals, including Indian herbal medicines, and manufacturers must follow quality, safety, and efficacy standards.

Title:

Content: Explainers
NEWS
12 hours ago

Does India Have Patience, Will And Resources To Build World's Top Cannabis Medicine Industry?

Raghav PriyadarshiUpdated on Mar 27, 2022, 16:03 IST

Consider the size of the opportunity — today’s billion dollar global medical cannabis industry is expected to hit USD 100 billion by 2028. That’s a 100x growth in the next six years.

We’ve missed the bus once — India is the largest producer and exporter of licit opium in the world, contributing over 50% of global volumes. Yet there is not a single Indian firm that is a global leader in manufacturing opioid medications, a USD 40 billion market annually!

Unspash/Representational image

On the back of successful medical cannabis regimes in countries such as Canada, Germany and increasingly the United States, hundreds of thousands of patients are able to access medical cannabis to treat a host of chronic conditions, most of which do not have safe or effective treatment pathways – neuropathic pains such as sciatica, fibromyalgia, and cancer-related pains; rheumatic conditions such as arthritis and multiple sclerosis; neurological conditions such as insomnia, migraine and Parkinson’s; or the ever increasing burden of mental health issues such as anxiety and depression – all conditions in which cannabinoid medicine has demonstrated ground-breaking results.

In this scenario, it is important to remember and highlight that India has the oldest medical cannabis regime in the world – in the form of Ayurveda – which records over 200 classical cannabis-based formulations. While Ayurveda recognises cannabis as a medicinal plant, allopathy does not.

Thus, modern formulations containing cannabis compounds cannot be manufactured and marketed with approvals from India’s drug regulator, until clinical research establishes the safety and efficacy of cannabis compounds in treating any particular condition. The onus is thus on the Indian pharmaceutical industry to undertake the required research to establish cannabinoids as therapeutic agents.

Unsplash/Representational image

Plant-derived drugs have tremendous potential, and the global pharma industry has barely scratched the surface of developing modern therapeutic formulations from medicinal plants. A case in point is ‘Artemisinin’, first extracted from Sweet Wormwood by Tu Youyou, a Chinese chemist who was awarded the Nobel Prize for Medicine in 2015 for demonstrating the efficacy of Artemisinin in treating malaria.

Tu Youyou drew inspiration from Traditional Chinese Medicine texts to find a cure for malaria, texts which prescribed using Sweet Wormwood to treat various fevers. Similarly, India too enjoys a unique position to build on the thousands of years of traditional medical knowledge contained in Ayurveda, to create novel therapeutics for unmet medical needs of the 21st century.

Cannabinoid medicine is projected to be the fastest growing life-sciences sector over the coming decade. Tapping this opportunity requires a change in mindset of Indian pharma, graduating from generic medicine manufacturing to R&D-based novel drug development. India has the necessary ecosystem – scientists, clinicians, researchers, a large drug manufacturing ecosystem and very large patient population – to really catapult the Indian life-sciences industry, and in particular cannabinoid therapeutics firms into global leaders.

Unsplash/Representational image

Cannabinoids have the potential to capture a significant share of this market with safer and effective alternatives to opioids and other analgesic medicines. The Indian drugs regulator has even issued regulations for a new class of plant-based drugs – ‘phytopharmaceuticals’ – a perfect bridge between traditional medicine manufacturing and modern allopathy.

Yet, seven years after the establishment of this hybrid regulatory regime, the Indian pharmaceutical industry is yet to respond with novel formulations registered under this category of medicine. It is high time we change our mindset, focus on value-added drug development, play by the rules of global pharma with respect to quality, safety and efficacy standards, and win!

The author is the founder and Chief Executive Officer of Savikalpa Sciences, a cannabinoid-focussed pharmaceutical firm. The views expressed in the article are author's own.

Schedule M is to be revised to meet WHO standards, making Good Manufacturing Practices (GMP) mandatory for pharma companies, including those producing Indian herbal medicines.

Title:

Content: Schedule M likely to be revised to bring it closer to WHO standards

The draft rules, still under consideration, include provisions to strengthen quality control and the safety of drugs manufactured in India

Anjali SinghSanket Koul New Delhi/Mumbai

4 min read Last Updated : Oct 1 2023 | 7:49 PM IST

A notification for revising Schedule M (of the Drugs and Cosmetics Rules, 1945) may be released soon to help Indian pharma companies adopt good manufacturing practices (GMP) as prescribed by the World Health Organization (WHO), a senior government official said.

The Drugs Controller General of India (DCGI), Rajiv Singh Raghuvanshi, said at a conference revised Schedule M would bring the industry on a par with global standards.

The move has come after the WHO raised concern when cough syrups exported by some Indian companies were allegedly responsible for the deaths of children abroad.

Adopting GMP in accordance with revised Schedule M was made mandatory for all pharma companies, including micro, small and medium companies, last month. Manufacturers having an annual turnover of less than Rs 250 crore had to complete their certification process within 12 months, whereas those with over Rs 250 crore were given six months to do so.

The draft rules, still under consideration, include provisions to strengthen quality control and the safety of drugs manufactured in India.

Meanwhile, to explain these changes and ensure compliance with them, the Central Drugs Standard Control Organisation (CDSCO) has conducted a one-day workshop in Mumbai.

Eswara Reddy, joint drug controller, CDSCO, said one of the most important changes proposed in the new draft rules was introducing a comprehensive system for change control.

“Under the current rules, manufacturers are only required to notify the CDSCO of significant changes to their manufacturing processes. The new draft rules would require manufacturers to classify all changes as minor, major, or critical, and to implement appropriate controls for each type of change. This would help to ensure that any changes in manufacturing processes are evaluated and managed to minimise the risk of product contamination or quality problems,” Reddy said.

The revision introduces the pharmaceutical quality system, quality risk management, product quality review, and qualifying and validating equipment, change control management, self-inspection, and stability studies in accordance with recommended climate conditions. Another important change proposed in the new draft rules is that manufacturers need to have a qualified and validated computerised storage system for all drug products, ensuring that drugs are stored in right conditions and that their quality is maintained throughout the supply chain. The draft rules also introduce validated cleaning procedures, working standards, and identity tests for starting materials. Additionally, they extend the retesting period for materials and call for including weighing areas, audit trails, and measures to prevent cross-contamination. Detailed guidelines for good production practices, deviation control, and equipment storage after cleaning have also been incorporated.

The ongoing risk-based inspections might have prompted the government to reassess the current GMP regulations and quality management systems followed by pharmaceutical manufacturers.

GMP, which include standards for materials, methods, machines, processes, personnel, and facilities, was first introduced in 1988 under Schedule M. This is the first amendment since June 2005.

The government has been trying to implement regulatory reforms in the pharma sector for the past few months. This includes regular meetings with state controllers to ensure harmonisation in the workings of the departments. Highlighting India’s desire to be a permanent member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, the DCGI said: “We have been accorded observer status but the ball is in their court as far as inviting us for membership is concerned.”

The DCGI said 99 per cent of the spurious products found during the past two to three years were among the top 300 medicine brands in India.

To counter this, the CDSCO will develop a digital regulatory ecosystem to look into grievances and impacts caused by the spurious industry.

The CDSCO has raided several labs that made spurious medicines.

Topics :World Health OrganisationPharma CompaniesMSMEspharmaceutical firms

First Published: Oct 1 2023 | 7:38 PM IST

Next Story

What is the World Health Organization doing to promote traditional medicine, including Ayurveda?

Establishing rules for the safe, fair, and effective use of traditional medicine